Polyp REcognition Assisted by a Device Interactive Characterization Tool - The PREDICT Study

Artificial Intelligence Clinical Trial

— PREDICT  

Official title:

Polyp REcognition Assisted by a Device Interactive Characterization Tool - The PREDICT Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04589078
• Other study ID #: CB-17-08/05
• Status: Completed
• Start date: September 8, 2020
• Est. completion date: December 22, 2020

Study information

• Verified date: May 2021
• Source: Cosmo Pharmaceuticals NV
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Diminutive colorectal polyps (≤ 5 mm) represent most of the polyps detected during colonoscopy, especially in the rectum-sigmoid tract. The characterization of these polyps by virtual chromoendoscopy is recognized as a key element for innovative imaging techniques. As a matter of facts diminutive colorectal polyps are very frequent and, if located in the rectosigmoid colon, they present a very low malignant risk (0.3% of evolution towards advanced adenoma and up to 0.08% of evolution towards invasive carcinoma). The real-time characterization would allow to identify the lowest risk polyps (hyperplastic subtype), to leave them in situ or, if resected, not to send them for histological examination, allowing a huge saving in healthcare associated costs.

Recently, the American Society for Gastrointestinal Endoscopy (ASGE) Technology Committee established the Preservation and Incorporation of Valuable endoscopic Innovations (PIVI) document, specific for real-time histological assessment for tiny colorectal polyps, to establish reference quality thresholds. Two performance standards have been developed to guide the use of advanced imaging:

1. for diminutive polyps to be resected and discarded without pathologic assessment, endoscopic technology (when used with high confidence) used to determine histology of polyps ≤ 5mm in size, when combined with the histopathology assessment of polyps > 5 mm in size, should provide a ≥ 90% agreement in assignment of post-polypectomy surveillance intervals when compared to decisions based on pathology assessment of all identified polyps;

2. in order for a technology to be used to guide the decision to leave suspected rectosigmoid hyperplastic polyps ≤ 5 mm in size in place (without resection), the technology should provide ≥ 90% negative predictive value (when used with high confidence) for adenomatous histology.

Computer-Aided-Diagnosis (CAD) is an artificial intelligence-based tool that would allow rapid and objective characterization of these lesions. The GI Genius CADx was developed to help endoscopists in their clinical practices for polyps characterization.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: December 22, 2020
• Est. primary completion date: December 22, 2020
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients aged 40-80 undergoing screening colonoscopy for CRC

• Ability to provide written, informed consent (approved by EC) and understand the responsibilities of trial participation.

Exclusion Criteria:

• subjects positive to Fecal Immunochemical Test or Fecal Occult Blood Test;

• subjects undergoing CRC surveillance colonoscopy

• subject at high risk for CRC

• subjects with a personal history of CRC, IBD or hereditary polyposic or non-polyposic syndromes;

• patients with previous resection of the sigmoid rectum;

• patients on anticoagulant therapy, which precludes resection / removal operations due to histopathological findings;

• patients who perform an emergency colonoscopy.

Related Conditions & MeSH terms

• Artificial Intelligence

Intervention

Device:
• GI Genius CADe system
Each patient will undergo standard white-light colonoscopy with the support of the latest version of the CE marked GI Genius CADe available.

Locations

Country	Name	City	State
Italy	Endoscopy Unit, Humanitas Research Hospital	Rozzano	Milano

Sponsors (1)

Lead Sponsor	Collaborator
Cosmo Artificial Intelligence-AI Ltd

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Sensitivity, Specificity, Accuracy, PPV and NPV of GI Genius CADx histology prediction and endoscopist assessment on all the identified lesions		1 day
Primary	Negative Predictive Value of histology prediction on diminutive (=5 mm) rectosigmoid polyps		1 day
Secondary	Agreement in assignment of post-polypectomy surveillance intervals	Agreement in assignment of post-polypectomy surveillance intervals according to established guidelines between: the assignment identified according to the combined; GI Genius CADx histology prediction for diminutive (=5 mm) polyps and; histology for larger polyps (> 5 mm), and; the assignment identified according to histology only.	1 day